Allergan Defends 3-Month Exclusivity Deal For Namenda

By John Kennedy · March 17, 2017, 6:48 PM EDT

Pharmaceutical patent holders that sue generic-drug manufacturers for infringement and then shorten product exclusivity periods via settlements shouldn't have to actually win those cases to maintain exclusivity, an Allergan unit told...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Response in Opposition to Motion

Case Information

Case Title

In Re Namenda Direct Purchaser Antitrust Litigation

Case Number

Court

New York Southern

Nature of Suit

Anti-Trust

Date Filed

September 22, 2015

Recent Articles By John

March 06, 2019
Ky. Hospital Sues Travelers For $10M Over Shoddy Building
July 03, 2018
NY Panel Revives NYU Sandy Damage Claims Against Turner
March 01, 2018
HHS Must Reconsider Formula For ACA Payments
February 13, 2018
11th Circ. Asked To Rehear Amgen, Pfizer Win In Enbrel Suit
February 07, 2018
Epic Beats Whistleblower's 'Woefully Deficient' FCA Suit
February 06, 2018
UPenn Hospital Can't Yet Exit Brain-Damage Suit, Judge Says
February 06, 2018
Docs Call Cigna's 11th Circ. Appeal Over $25M Deal Premature
February 05, 2018
Ex-Doc Gets 8 Years For Fraud, Illegally Dispensing Opioids
February 05, 2018
Navajo Nation Sues HHS Over $7.2M Education Program Cut
February 02, 2018
2nd Circ. Affirms Dismissal Of Dr. Scholl's Class Action